Wall Street brokerages expect GTx, Inc. (NASDAQ:GTXI) to report ($0.39) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for GTX’s earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.36). GTX reported earnings of ($0.44) per share during the same quarter last year, which indicates a positive year over year growth rate of 11.4%. The firm is expected to report its next earnings results on Wednesday, March 21st.

On average, analysts expect that GTX will report full year earnings of ($1.61) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.48). For the next year, analysts expect that the firm will post earnings of ($1.68) per share, with EPS estimates ranging from ($1.69) to ($1.66). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for GTX.

GTX (NASDAQ:GTXI) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25).

Several equities research analysts recently issued reports on GTXI shares. Stifel Nicolaus started coverage on shares of GTX in a report on Thursday, November 9th. They issued a “buy” rating for the company. Robert W. Baird started coverage on shares of GTX in a report on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 target price for the company.

Shares of GTX (NASDAQ:GTXI) opened at $12.10 on Friday. GTX has a fifty-two week low of $2.73 and a fifty-two week high of $12.96.

A number of institutional investors have recently added to or reduced their stakes in GTXI. Bank of New York Mellon Corp purchased a new stake in GTX in the 2nd quarter worth approximately $124,000. Caxton Corp purchased a new stake in GTX in the 3rd quarter worth approximately $531,000. Finally, Abingworth LLP purchased a new stake in GTX in the 3rd quarter worth approximately $2,781,000. 9.02% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/gtx-inc-gtxi-expected-to-announce-earnings-of-0-39-per-share/1727164.html.

About GTX

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.